New combo attack on Tough-to-Treat breast cancer

NCT ID NCT04468061

Summary

This study is testing whether adding an immunotherapy drug (pembrolizumab) to a targeted chemotherapy drug (sacituzumab govitecan) works better than the chemotherapy drug alone. It is for people with a specific, hard-to-treat type of advanced breast cancer (triple-negative and PD-L1-negative) that has spread. The main goal is to see which approach better delays the cancer from getting worse.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • DF/BWCC in Clinical Affiliation with South Shore Hospital

    RECRUITING

    South Weymouth, Massachusetts, 02190, United States

    Contact Email: •••••@•••••

    Contact

  • DFCI @ Foxborough

    RECRUITING

    Foxborough, Massachusetts, 02035, United States

    Contact Email: •••••@•••••

    Contact

  • DFCI @ Milford Regional Hospital

    RECRUITING

    Milford, Massachusetts, 01757, United States

    Contact Email: •••••@•••••

    Contact

  • Dana Farber Cancer Institute

    RECRUITING

    Boston, Massachusetts, 02215, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Eastern Maine Medical Center

    RECRUITING

    Brewer, Maine, 04412, United States

    Contact Email: •••••@•••••

    Contact

  • Medical University of South Carolina

    RECRUITING

    Charleston, South Carolina, 29425, United States

    Contact Email: •••••@•••••

    Contact

    Contact

  • Miami Cancer Institute at Baptist Health

    RECRUITING

    Plantation, Florida, 33324, United States

    Contact Email: •••••@•••••

    Contact

  • Miami Cancer Institute at Baptist Health (Kendall)

    RECRUITING

    Miami, Florida, 33176, United States

    Contact Email: •••••@•••••

    Contact

  • Ohio State University Medical Center

    RECRUITING

    Columbus, Ohio, 43212, United States

    Contact Email: •••••@•••••

    Contact

  • Sarah Cannon Research Institute

    RECRUITING

    Chattanooga, Tennessee, 37404, United States

    Contact Email: •••••@•••••

    Contact

  • Stamford Hospital

    RECRUITING

    Stamford, Connecticut, 06904, United States

    Contact Email: •••••@•••••

    Contact

  • The Christ Hospital Cancer Center

    RECRUITING

    Cincinnati, Ohio, 45219, United States

    Contact Email: •••••@•••••

    Contact

  • The University of North Carolina at Chapel Hill

    RECRUITING

    Chapel Hill, North Carolina, 27599, United States

    Contact Email: •••••@•••••

    Contact

  • University of Chicago Medical Center

    RECRUITING

    Chicago, Illinois, 60637, United States

    Contact Email: •••••@•••••

    Contact

  • University of Pennsylvania-Abramson Cancer Center

    RECRUITING

    Philadelphia, Pennsylvania, 19104, United States

    Contact Email: •••••@•••••

    Contact

Conditions

Explore the condition pages connected to this study.